HC Wainwright reissued their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA - Free Report) in a research report released on Monday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. HC Wainwright also issued estimates for Tyra Biosciences' Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.37) EPS.
A number of other analysts have also recently issued reports on the company. Wedbush reissued an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences has a consensus rating of "Buy" and an average target price of $30.83.
Get Our Latest Stock Report on TYRA
Tyra Biosciences Stock Down 8.0 %
TYRA traded down $0.66 on Monday, reaching $7.64. The company's stock had a trading volume of 163,348 shares, compared to its average volume of 236,807. Tyra Biosciences has a fifty-two week low of $7.55 and a fifty-two week high of $29.60. The stock has a 50 day moving average of $11.88 and a two-hundred day moving average of $16.03. The company has a market capitalization of $386.61 million, a price-to-earnings ratio of -4.76 and a beta of 1.09.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. As a group, analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.
Insider Transactions at Tyra Biosciences
In related news, Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the transaction, the director now directly owns 3,707,420 shares of the company's stock, valued at $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 21,998 shares of company stock worth $344,818 over the last 90 days. 15.40% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Tyra Biosciences
Institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. increased its holdings in shares of Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock valued at $147,858,000 after purchasing an additional 220,681 shares in the last quarter. Alta Partners Management Company L.P. purchased a new position in Tyra Biosciences in the fourth quarter valued at about $56,716,000. FMR LLC increased its holdings in Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company's stock valued at $79,296,000 after buying an additional 26,187 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Tyra Biosciences during the 4th quarter valued at approximately $28,185,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Tyra Biosciences by 63.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company's stock worth $24,291,000 after acquiring an additional 679,124 shares in the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
See Also
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
